共 100 条
[1]
Bliuc D(2009)Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513-521
[2]
Nguyen ND(2005)Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 229-238
[3]
Milch VE(2000)Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118-4124
[4]
Nguyen TV(2001)Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333-340
[5]
Eisman JA(2008)Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures Curr Med Res Opin 24 3217-3222
[6]
Center JR(2007)A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023-1031
[7]
Kanis JA(2005)Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453-1460
[8]
Johnell O(2005)Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures J Clin Endocrinol Metab 90 1583-1587
[9]
Black DM(2010)American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Care Res 62 1515-1526
[10]
Thompson DE(2001)Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434-1441